Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-20

Clinical Trial Update: RDEA3170 and Allopurinol Combination Study in Gout Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating RDEA3170 in combination with allopurinol for gout; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Allopurinol (Allopurinol)
  • RDEA3170 (RDEA3170)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 1 | Status: COMPLETED | Results posted: 2017-12-20